In Russia, the incidence of melanoma is increasing steadily. The approved standard of specialized medical care for melanoma of the skin defi ned the range of drugs, recommended for the provision of quality health care. However, it appears that the most effective innovative and safe medicines are at the same time the most expensive drugs. The most important is the assessment of drug use, taking into account their relative effi cacy, safety (risk/benefi t) and cost (economic effi ciency), which may help to create the conditions for controlling their use. Based on this analysis, it is necessary to introduce drugs on the lists of drugs within the framework of the provision of state guarantees of free medical care to citizens (patients).
